Bispecific antibodies enhance tumor‐infiltrating T cell cytotoxicity against autologous HER‐2‐expressing high‐grade ovarian tumors
出版年份 2019 全文链接
标题
Bispecific antibodies enhance tumor‐infiltrating T cell cytotoxicity against autologous HER‐2‐expressing high‐grade ovarian tumors
作者
关键词
-
出版物
JOURNAL OF LEUKOCYTE BIOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-12-13
DOI
10.1002/jlb.5ma1119-265r
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells
- (2018) Hans H. Oberg et al. Frontiers in Immunology
- Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells
- (2018) Sonja Lieber et al. OncoImmunology
- Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer
- (2018) Emelie Rådestad et al. OncoImmunology
- Recent advances of bispecific antibodies in solid tumors
- (2017) Shengnan Yu et al. Journal of Hematology & Oncology
- The making of bispecific antibodies
- (2017) Ulrich Brinkmann et al. mAbs
- An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
- (2017) Takahiro Ishiguro et al. Science Translational Medicine
- The Ambiguous Role of γδ T Lymphocytes in Antitumor Immunity
- (2017) Guranda Chitadze et al. TRENDS IN IMMUNOLOGY
- The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
- (2017) Thomas Worzfeld et al. Frontiers in Oncology
- Tumor microenvironment: The culprit for ovarian cancer metastasis?
- (2016) Zhongyue Luo et al. CANCER LETTERS
- Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients
- (2016) Hans-Heinrich Oberg et al. PANCREATOLOGY
- Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
- (2016) Ruea-Yea Huang et al. OncoImmunology
- Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer
- (2016) Jashodeep Datta et al. JAMA Oncology
- The prognostic landscape of genes and infiltrating immune cells across human cancers
- (2015) Andrew J Gentles et al. NATURE MEDICINE
- Progressive loss of anti-HER2 CD4+T-helper type 1 response in breast tumorigenesis and the potential for immune restoration
- (2015) Jashodeep Datta et al. OncoImmunology
- HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development
- (2014) J C Singh et al. BRITISH JOURNAL OF CANCER
- Novel Bispecific Antibodies Increase T-Cell Cytotoxicity against Pancreatic Cancer Cells
- (2014) H.-H. Oberg et al. CANCER RESEARCH
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
- (2014) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy
- (2014) Hans-Heinrich Oberg et al. Frontiers in Immunology
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- CD1d-lipid antigen recognition by the γδ TCR
- (2013) Adam P Uldrich et al. NATURE IMMUNOLOGY
- Antitumor properties of salinomycin on cisplatin-resistant human ovarian cancer cells in vitro and in vivo: Involvement of p38 MAPK activation
- (2013) BEI ZHANG et al. ONCOLOGY REPORTS
- Identification of Ovarian Cancer Metastatic miRNAs
- (2013) Souriya Vang et al. PLoS One
- Pertuzumab: new hope for patients with HER2-positive breast cancer
- (2012) M. Capelan et al. ANNALS OF ONCOLOGY
- The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells
- (2012) P Glorius et al. LEUKEMIA
- Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes
- (2011) Dongmei Lai et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) N. Colombo et al. ANNALS OF ONCOLOGY
- Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
- (2009) David M. Gershenson et al. GYNECOLOGIC ONCOLOGY
- Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
- (2008) Alessandro D. Santin et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started